A5006549421- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Urologic and reproductive health conditions
- Bladder and Urothelial Cancer Treatments
- Renal cell carcinoma treatment
- Radiomics and Machine Learning in Medical Imaging
- Renal and related cancers
- Urinary and Genital Oncology Studies
- Economic and Financial Impacts of Cancer
- MRI in cancer diagnosis
- Urological Disorders and Treatments
- Pediatric Urology and Nephrology Studies
- Advanced Radiotherapy Techniques
- Genital Health and Disease
- Cardiac, Anesthesia and Surgical Outcomes
- Cancer, Lipids, and Metabolism
- Surgical Simulation and Training
- Enhanced Recovery After Surgery
- Pelvic floor disorders treatments
- Renal and Vascular Pathologies
- Multiple and Secondary Primary Cancers
- Metabolism, Diabetes, and Cancer
- Global Cancer Incidence and Screening
- Frailty in Older Adults
- Health Systems, Economic Evaluations, Quality of Life
Duke University Hospital
2022-2025
Duke Medical Center
2022-2025
Duke Cancer Institute
2022-2023
Duke University
2023
Maimonides Medical Center
2019-2022
Center for Brooklyn History
2019
North Shore Diabetes and Endocrine Associates
2018
New York Proton Center
2014
Medical College of Wisconsin
2014
Columbia University
2014
Purpose: SpaceOAR® is a Food and Drug Administration-approved hydrogel injection used to create space between the prostate rectum during radiotherapy. It has shown significantly reduce rectal radiation dose with lower rates of toxicity. Despite high safety performance in initial trials, SpaceOAR remains early clinical use. Thus, we examined emerging reports as system becomes more widely utilized. Methods: We reviewed manufacturer website for profile complications associated hydrogel. then...
Background This study reports the oncological and functional outcomes in men with localized prostate cancer (Pca) who were treated primary whole gland cryoablation (WGC) of prostate. Methods The authors retrospectively reviewed their prospectively collected cryosurgery database between January 2002 September 2019 for WGC at a tertiary referral center. Primary outcome includes biochemical recurrence‐free survival (BRFS). Secondary include failure‐free (FFS), metastasis‐free (MFS) adverse...
Renal cell carcinoma is identified most often in the sixth or seventh decade of life, coinciding with rise incidental diagnosis small renal masses as imaging technology has advanced. However, not all patients this older age group are surgical candidates owing to their comorbidities. Cryoablation a well-established minimally invasive technique for treatment masses. The advent less ablative alleviated dilemma certain who contraindicated extirpative procedures. With appropriate patient...